> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/author_index.md).

# AUTHOR\_INDEX

## BREXAtlas™ Encyclopedia — Search by Author

**Purpose:** This index lets readers search the BREXAtlas Encyclopedia by author, research group, or source paper instead of needing to know the BRE number first.

**Coverage:** BRE-001 through BRE-044\
**Companion Navigation Files:** `TABLE_OF_CONTENTS.md`, `CELL_LINE_INDEX.md`, `TISSUE_INDEX.md`, `SUBJECT_INDEX.md`, `MECHANISM_INDEX.md`, `FREQUENCY_INDEX.md`, `DISCOVERY_ATLAS.md`, and `RESEARCH_GAP_ATLAS.md`

***

## Quick Author-to-BRE Table

| BRE     | Author / Group          | Year | Source PDF                          | Primary Subject                                                | Encyclopedia Entry                                                   |
| ------- | ----------------------- | ---: | ----------------------------------- | -------------------------------------------------------------- | -------------------------------------------------------------------- |
| BRE-001 | Kirson et al.           | 2007 | `Kirson_2007.pdf`                   | Foundational TTFields growth suppression                       | [`BRE-001`](/bre-001.md)                                             |
| BRE-002 | Porat et al.            | 2017 | `Porat_2017.pdf`                    | Frequency optimization and tissue-specific response            | [`BRE-002`](/bre-001/bre-002.md)                                     |
| BRE-003 | Giladi et al.           | 2017 | `Giladi_2017.pdf`                   | DNA repair suppression after radiation                         | [`BRE-003`](/bre-001/bre-003.md)                                     |
| BRE-004 | Giladi et al.           | 2014 | `Giladi_2014.pdf`                   | Pancreatic cancer mitotic disruption and reduced clonogenicity | [`BRE-004`](/bre-001/bre-004.md)                                     |
| BRE-005 | Voloshin et al.         | 2020 | `Voloshin_2020.pdf`                 | Immunogenic cell death and anti-PD-1 combination               | [`BRE-005`](/bre-001/bre-005.md)                                     |
| BRE-006 | Levin et al.            | 2025 | `Levin_2025.pdf`                    | Systems bioelectricity framework                               | [`BRE-006`](/bre-001/bre-006.md)                                     |
| BRE-007 | Mathews et al.          | 2025 | `Mathews_2025.pdf`                  | Cancer bioelectricity research ecosystem                       | [`BRE-007`](/bre-001/bre-007.md)                                     |
| BRE-008 | Pai et al.              | 2024 | `Pai_2024.pdf`                      | Bioelectricity across development, regeneration, and cancer    | [`BRE-008`](/bre-001/bre-008.md)                                     |
| BRE-009 | ALSUntangled            | 2014 | `ALSUntangled_2014.pdf`             | Evaluation of electromagnetic treatment claims                 | [`BRE-009`](/bre-001/bre-009.md)                                     |
| BRE-010 | Zhao et al.             | 2026 | `Zhao_2026.pdf`                     | AI and predictive bioelectric oncology                         | [`BRE-010`](/bre-001/bre-010.md)                                     |
| BRE-011 | Godinho et al.          | 2025 | `Godinho_2025.pdf`                  | Computational bioelectric modeling                             | [`BRE-011`](/bre-001/bre-011.md)                                     |
| BRE-012 | Savencu et al.          | 2025 | `Savencu_2025.pdf`                  | Cancer as a complex adaptive system                            | [`BRE-012`](/bre-001/bre-012.md)                                     |
| BRE-013 | Han et al.              | 2025 | `Han_2025.pdf`                      | Human activity networks and systems theory                     | [`BRE-013`](/bre-001/bre-013.md)                                     |
| BRE-014 | Giladi et al.           | 2015 | `Giladi_ScientificReports_2015.pdf` | Mitotic structural collapse                                    | [`BRE-014`](/bre-001/bre-014.md)                                     |
| BRE-015 | Gera et al.             | 2015 | `Gera.pdf`                          | Septin mislocalization                                         | [`BRE-015`](/bre-001/bre-015.md)                                     |
| BRE-016 | Berkelmann et al.       | 2019 | `Berkelmann.pdf`                    | Cytokinetic furrow destabilization                             | [`BRE-016`](/bre-001/bre-016.md)                                     |
| BRE-017 | Kessler et al.          | 2018 | `Kessler.pdf`                       | Spindle assembly checkpoint vulnerability                      | [`BRE-017`](/bre-001/bre-017.md)                                     |
| BRE-018 | Karanam et al.          | 2017 | `Karanam2.pdf`                      | NSCLC radiation sensitization and DNA repair suppression       | [`BRE-018`](/bre-001/bre-018.md)                                     |
| BRE-019 | Karanam & Story         | 2021 | `Karanam.pdf`                       | Replication stress vulnerability / TTFields mechanism review   | [`BRE-019`](/bre-001/bre-019.md)                                     |
| BRE-020 | Tanzhu et al.           | 2022 | `Tanzhu.pdf`                        | Combination therapy amplification                              | [`BRE-020`](/bre-001/bre-020.md)                                     |
| BRE-021 | Zang et al.             | 2025 | `Zang.pdf`                          | Frequency and field optimization                               | [`BRE-021`](/bre-001/bre-021.md)                                     |
| BRE-022 | Yoon et al.             | 2020 | `Yoon.pdf`                          | Ferroelectric nanoparticle TTFields amplification              | [`BRE-022`](/bre-001/bre-022.md)                                     |
| BRE-023 | Berzingi et al.         | 2016 | `Berzingi.pdf`                      | Membrane potential and ion-channel dysregulation               | [`BRE-023`](/bre-001/bre-023.md)                                     |
| BRE-024 | Sadeghipour et al.      | 2012 | `Sadeghipour.pdf`                   | Calcium signaling, ROS, and oxidative stress                   | [`BRE-024`](/bre-001/bre-024.md)                                     |
| BRE-025 | Cameron et al.          | 2014 | `Cameron.pdf`                       | Anti-angiogenesis and tumor vascular suppression               | [`BRE-025`](/bre-001/bre-025.md)                                     |
| BRE-026 | Yang & Brackenbury      | 2013 | `Yang.pdf`                          | Membrane potential and cancer progression                      | [`BRE-026`](/bre-001/bre-026.md)                                     |
| BRE-027 | Hassan & El-Shenawee    | 2011 | `Hassan.pdf`                        | Electromagnetic detection and diagnostics                      | [`BRE-027`](/bre-001/bre-027.md)                                     |
| BRE-028 | Chen et al.             | 2010 | `Chen.pdf`                          | Environmental EMF risk meta-analysis                           | [`BRE-028`](/bre-001/bre-028.md)                                     |
| BRE-029 | Brainard et al.         | 1999 | `Brainard.pdf`                      | Melatonin and circadian signaling hypothesis                   | [`BRE-029`](/bre-001/bre-029.md)                                     |
| BRE-030 | Sharma et al.           | 2019 | `Sharma_2019.pdf`                   | CACNA1H and RF frequency targeting                             | [`BRE-030`](broken://pages/3cb86c178317a0a18b913882e2a589d6ce39b2ac) |
| BRE-031 | Sheth & Esfandiari      | 2022 | `Sheth_2022.pdf`                    | Bioelectric dysregulation in cancer                            | [`BRE-031`](/bre-001/bre-031.md)                                     |
| BRE-032 | Buckner et al.          | 2015 | `Buckner_2015.pdf`                  | T-type calcium channel vulnerability                           | [`BRE-032`](/bre-001/bre-032.md)                                     |
| BRE-033 | Jang et al.             | 2022 | `Jang_2022.pdf`                     | TTFields and sorafenib combination                             | [`BRE-033`](/bre-001/bre-033.md)                                     |
| BRE-034 | Davidi et al.           | 2022 | `Davidi_2022.pdf`                   | Autophagy, ER stress, and sorafenib amplification              | [`BRE-034`](/bre-001/bre-034.md)                                     |
| BRE-035 | Sharpe et al.           | 2021 | `Sharpe_2021.pdf`                   | Mitochondrial respiration disruption                           | [`BRE-035`](/bre-001/bre-035.md)                                     |
| BRE-036 | Rominiyi et al.         | 2020 | `Rominiyi.pdf`                      | Clinical TTFields translation                                  | [`BRE-036`](/bre-001/bre-036.md)                                     |
| BRE-037 | Ceresoli & Gianoncelli  | 2025 | `Ceresoli.pdf`                      | Clinical thoracic TTFields                                     | [`BRE-037`](/bre-001/bre-037.md)                                     |
| BRE-038 | Chen et al.             | 2025 | `Chen1.pdf`                         | TTFields safety and tolerability                               | [`BRE-038`](/bre-001/bre-038.md)                                     |
| BRE-039 | Lee & Kim               | 2022 | `Lee.pdf` / Lee2 alias              | Doxorubicin and radiation amplification                        | [`BRE-039`](/bre-001/bre-039.md)                                     |
| BRE-040 | Lee et al.              | 2023 | `Lee2.pdf` / Lee3 alias             | Sarcoma TTFields sensitization                                 | [`BRE-040`](/bre-001/bre-040.md)                                     |
| BRE-041 | Cho et al.              | 2025 | `Cho.pdf`                           | Ferroelectric nanoparticle field amplification                 | [`BRE-041`](/bre-001/bre-041.md)                                     |
| BRE-042 | Schlieper-Scherf et al. | 2024 | `Schlieper-Scherf.pdf`              | Tumor microtube network disruption                             | [`BRE-042`](/bre-001/bre-042.md)                                     |
| BRE-043 | Zimmerman et al.        | 2013 | `Zimmerman.pdf`                     | Tumor-specific RF frequencies                                  | [`BRE-043`](/bre-001/bre-043.md)                                     |
| BRE-044 | Mothersill et al.       | 2006 | `Mothersill.pdf`                    | Bioelectric bystander signaling                                | [`BRE-044`](/bre-001/bre-044.md)                                     |

***

## Alphabetical Author Lookup

### ALSUntangled

* **BRE-009** — 2014 — Evaluation of electromagnetic treatment claims\
  Entry: [`BRE-009`](/bre-001/bre-009.md)

### Berkelmann et al.

* **BRE-016** — 2019 — Cytokinetic furrow destabilization\
  Entry: [`BRE-016`](/bre-001/bre-016.md)

### Berzingi et al.

* **BRE-023** — 2016 — Membrane potential and ion-channel dysregulation\
  Entry: [`BRE-023`](/bre-001/bre-023.md)

### Brainard et al.

* **BRE-029** — 1999 — Melatonin and circadian signaling hypothesis\
  Entry: [`BRE-029`](/bre-001/bre-029.md)

### Buckner et al.

* **BRE-032** — 2015 — T-type calcium channel vulnerability\
  Entry: [`BRE-032`](/bre-001/bre-032.md)

### Cameron et al.

* **BRE-025** — 2014 — Anti-angiogenesis and tumor vascular suppression\
  Entry: [`BRE-025`](/bre-001/bre-025.md)

### Ceresoli & Gianoncelli

* **BRE-037** — 2025 — Clinical thoracic TTFields\
  Entry: [`BRE-037`](/bre-001/bre-037.md)

### Chen et al.

* **BRE-028** — 2010 — Environmental EMF risk meta-analysis\
  Entry: [`BRE-028`](/bre-001/bre-028.md)
* **BRE-038** — 2025 — TTFields safety and tolerability\
  Entry: [`BRE-038`](/bre-001/bre-038.md)

### Cho et al.

* **BRE-041** — 2025 — Ferroelectric nanoparticle field amplification\
  Entry: [`BRE-041`](/bre-001/bre-041.md)

### Davidi et al.

* **BRE-034** — 2022 — Autophagy, ER stress, and sorafenib amplification\
  Entry: [`BRE-034`](/bre-001/bre-034.md)

### Gera et al.

* **BRE-015** — 2015 — Septin mislocalization\
  Entry: [`BRE-015`](/bre-001/bre-015.md)

### Giladi et al.

* **BRE-003** — 2017 — DNA repair suppression after radiation\
  Entry: [`BRE-003`](/bre-001/bre-003.md)
* **BRE-004** — 2014 — Pancreatic cancer mitotic disruption and reduced clonogenicity\
  Entry: [`BRE-004`](/bre-001/bre-004.md)
* **BRE-014** — 2015 — Mitotic structural collapse\
  Entry: [`BRE-014`](/bre-001/bre-014.md)

### Godinho et al.

* **BRE-011** — 2025 — Computational bioelectric modeling\
  Entry: [`BRE-011`](/bre-001/bre-011.md)

### Han et al.

* **BRE-013** — 2025 — Human activity networks and systems theory\
  Entry: [`BRE-013`](/bre-001/bre-013.md)

### Hassan & El-Shenawee

* **BRE-027** — 2011 — Electromagnetic detection and diagnostics\
  Entry: [`BRE-027`](/bre-001/bre-027.md)

### Jang et al.

* **BRE-033** — 2022 — TTFields and sorafenib combination\
  Entry: [`BRE-033`](/bre-001/bre-033.md)

### Karanam & Story

* **BRE-019** — 2021 — Replication stress vulnerability / TTFields mechanism review\
  Entry: [`BRE-019`](/bre-001/bre-019.md)

### Karanam et al.

* **BRE-018** — 2017 — NSCLC radiation sensitization and DNA repair suppression\
  Entry: [`BRE-018`](/bre-001/bre-018.md)

### Kessler et al.

* **BRE-017** — 2018 — Spindle assembly checkpoint vulnerability\
  Entry: [`BRE-017`](/bre-001/bre-017.md)

### Kirson et al.

* **BRE-001** — 2007 — Foundational TTFields growth suppression\
  Entry: [`BRE-001`](/bre-001.md)

### Lee & Kim

* **BRE-039** — 2022 — Doxorubicin and radiation amplification\
  Entry: [`BRE-039`](/bre-001/bre-039.md)

### Lee et al.

* **BRE-040** — 2023 — Sarcoma TTFields sensitization\
  Entry: [`BRE-040`](/bre-001/bre-040.md)

### Levin et al.

* **BRE-006** — 2025 — Systems bioelectricity framework\
  Entry: [`BRE-006`](/bre-001/bre-006.md)

### Mathews et al.

* **BRE-007** — 2025 — Cancer bioelectricity research ecosystem\
  Entry: [`BRE-007`](/bre-001/bre-007.md)

### Mothersill et al.

* **BRE-044** — 2006 — Bioelectric bystander signaling\
  Entry: [`BRE-044`](/bre-001/bre-044.md)

### Pai et al.

* **BRE-008** — 2024 — Bioelectricity across development, regeneration, and cancer\
  Entry: [`BRE-008`](/bre-001/bre-008.md)

### Porat et al.

* **BRE-002** — 2017 — Frequency optimization and tissue-specific response\
  Entry: [`BRE-002`](/bre-001/bre-002.md)

### Rominiyi et al.

* **BRE-036** — 2020 — Clinical TTFields translation\
  Entry: [`BRE-036`](/bre-001/bre-036.md)

### Sadeghipour et al.

* **BRE-024** — 2012 — Calcium signaling, ROS, and oxidative stress\
  Entry: [`BRE-024`](/bre-001/bre-024.md)

### Savencu et al.

* **BRE-012** — 2025 — Cancer as a complex adaptive system\
  Entry: [`BRE-012`](/bre-001/bre-012.md)

### Schlieper-Scherf et al.

* **BRE-042** — 2024 — Tumor microtube network disruption\
  Entry: [`BRE-042`](/bre-001/bre-042.md)

### Sharma et al.

* **BRE-030** — 2019 — CACNA1H and RF frequency targeting\
  Entry: [`BRE-030`](/bre-001/bre-030.md)

### Sharpe et al.

* **BRE-035** — 2021 — Mitochondrial respiration disruption\
  Entry: [`BRE-035`](/bre-001/bre-035.md)

### Sheth & Esfandiari

* **BRE-031** — 2022 — Bioelectric dysregulation in cancer\
  Entry: [`BRE-031`](/bre-001/bre-031.md)

### Tanzhu et al.

* **BRE-020** — 2022 — Combination therapy amplification\
  Entry: [`BRE-020`](/bre-001/bre-020.md)

### Voloshin et al.

* **BRE-005** — 2020 — Immunogenic cell death and anti-PD-1 combination\
  Entry: [`BRE-005`](/bre-001/bre-005.md)

### Yang & Brackenbury

* **BRE-026** — 2013 — Membrane potential and cancer progression\
  Entry: [`BRE-026`](/bre-001/bre-026.md)

### Yoon et al.

* **BRE-022** — 2020 — Ferroelectric nanoparticle TTFields amplification\
  Entry: [`BRE-022`](/bre-001/bre-022.md)

### Zang et al.

* **BRE-021** — 2025 — Frequency and field optimization\
  Entry: [`BRE-021`](/bre-001/bre-021.md)

### Zhao et al.

* **BRE-010** — 2026 — AI and predictive bioelectric oncology\
  Entry: [`BRE-010`](/bre-001/bre-010.md)

### Zimmerman et al.

* **BRE-043** — 2013 — Tumor-specific RF frequencies\
  Entry: [`BRE-043`](/bre-001/bre-043.md)

***

## Author Disambiguation Notes

### Giladi et al.

Giladi appears in multiple TTFields entries and must not be routed as a single paper.

| BRE     | Year | Correct Role                                             |
| ------- | ---: | -------------------------------------------------------- |
| BRE-003 | 2017 | Glioma radiation and DNA repair delay                    |
| BRE-004 | 2014 | Pancreatic cancer TTFields and reduced clonogenicity     |
| BRE-014 | 2015 | Broad mitotic spindle disruption and mitotic catastrophe |

### Karanam Entries

| BRE     | Year | Correct Role                                                       |
| ------- | ---: | ------------------------------------------------------------------ |
| BRE-018 | 2017 | NSCLC radiation sensitization and DNA repair suppression           |
| BRE-019 | 2021 | TTFields multi-mechanism review and clinical-translation synthesis |

### Lee Entries

The Lee entries must remain separated because they describe different cancer models and treatment combinations.

| BRE                       | Year | Correct Role                                                                     |
| ------------------------- | ---: | -------------------------------------------------------------------------------- |
| BRE-039                   | 2022 | Lung cancer, A549/H460, TTFields + doxorubicin + radiation                       |
| BRE-040                   | 2023 | Liposarcoma, SW872/94T778, TTFields + doxorubicin                                |
| Pending future assignment | 2025 | MXenzyme-BECT / electric-pulse regulated MXene nanozymes; not BRE-039 or BRE-040 |

### Chen Entries

| BRE     | Year | Correct Role                                              |
| ------- | ---: | --------------------------------------------------------- |
| BRE-028 | 2010 | Environmental EMF exposure risk meta-analysis             |
| BRE-038 | 2025 | TTFields plus temozolomide adverse-outcomes meta-analysis |


---

# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.

## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:

```
GET https://www.brexatlas.org/author_index.md?ask=<question>&goal=<endgoal>
```

`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.

The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.